Enhancing the Outcome of Skills Training for People With Schizophrenia - Full Text View

Sponsored by:	National Institute of Mental Health (NIMH)
Information provided by:	National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier:	NCT00069433

Purpose

This study will determine the effectiveness of skills training in people with schizophrenia and the applicability of the acquired skills in the “real world.”

Condition	Intervention
Schizophrenia	Procedure: Social skills and symptom management training

MedlinePlus related topics: Schizophrenia

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title:	Skills Training for Schizophrenia: Enhancing Outcomes

Further study details as provided by National Institute of Mental Health (NIMH):

Estimated Enrollment:

60

Detailed Description:

People with schizophrenia have a large number of social and symptom management training programs available to them. Studies suggest that these training programs are effective, but their generalizability and effectiveness in outpatient settings has not been thoroughly examined. This study will examine the treatment outcomes of a skills training approach in schizophrenic individuals taking antipsychotic medication.

Participants taking stable doses of risperidone, olanzapine, or quetiapine will be randomly assigned to receive either intensive symptom management and social skills training or group therapy for 12 months. A verbal memory test will be used to stratify the randomization procedure and to control for neurocognitive functioning.

Eligibility

Ages Eligible for Study:	18 Years to 55 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Diagnosis of schizophrenia or schizoaffective disorder for > 5 years
Use of stable dose risperidone, olanzapine, or quetiapine for at least 1 month with no planned medication changes
Social Behavior Scale (SBS) score > 45
Willing and able to provide informed consent

Exclusion Criteria:

IQ < 70
Use of more than one antipsychotic medication
Use of benzodiazepines, tricyclic antidepressants, or anticholinergic medication commonly used to treat extrapyramidal symptoms
DSM-IV criteria for alcohol or other substance dependence
History of any traumatic brain injury leading to loss of consciousness for > 30 minutes
Diagnosis of a comorbid medical condition that could interfere with antipsychotic medication treatment or the ability to complete the study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00069433

Locations

United States, Connecticut
Hall-Brooke Behavioral Health Services
Westport, Connecticut, United States, 06880
Hall-Brooke-The Center
Bridgeport, Connecticut, United States, 06606

Sponsors and Collaborators

National Institute of Mental Health (NIMH)

More Information

Study ID Numbers:	R01 MH66362, DSIR AT-SP
Study First Received:	September 24, 2003
Last Updated:	November 17, 2005
ClinicalTrials.gov Identifier:	NCT00069433
Health Authority:	United States: Federal Government

Keywords provided by National Institute of Mental Health (NIMH):

Psychotic Disorders

Study placed in the following topic categories:

Schizophrenia
Mental Disorders
Psychotic Disorders
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on January 16, 2009